Back to results

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Primary Purpose

Dysphagia, Lung Cancer, Pain

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

Manuka honey in liquid form

Manuka honey in lozenge form

Standard supportive care

About this trial

This is an interventional supportive care trial for Dysphagia focused on measuring pain, dysphagia, recurrent non-small cell lung cancer, stage IA non-small cell lung cancer, stage IB non-small cell lung cancer, stage IIA non-small cell lung cancer, stage IIB non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, extensive stage small cell lung cancer, limited stage small cell lung cancer, recurrent small cell lung cancer, esophagitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

Patients being treated with combination chemotherapy (definitive or adjuvant) and radiation therapy once daily for small cell or non-small cell lung cancer (primary population for the trial)
- Patients can receive chemoradiotherapy while on a Radiation Therapy Oncology Group (RTOG) lung trial or while not being on a clinical trial
- No patients receiving chemoradiotherapy while enrolled on a single institution trial or trials coordinated by other cooperative groups
No patients with metastatic disease
At least 5 cm of the esophagus must be in the 60 Gy isodose volume in 1.6 to 2.0 Gy fractions

PATIENT CHARACTERISTICS:

Age 18 and up
Able to swallow thick liquids prior to treatment
Able to speak English or Spanish in order to complete required forms (verbal completion is adequate)
No patients with poorly controlled diabetes
No known hypersensitivity to honey

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No patients who have received prior chemotherapy or radiation therapy
No patients receiving more than once daily treatments
Therapeutic use of honey other than the Manuka honey provided for this trial is not allowed while patients are on study
Patients must also avoid honey-flavored medical products and/or sugary, viscous substances
Amifostine is not permitted

Sites / Locations

Providence Cancer Center at Providence Hospital
UCSF Helen Diller Family Comprehensive Cancer Center
Stanford Cancer Center
CCOP - Christiana Care Health Services
Baptist Cancer Institute - Jacksonville
CCOP - Mount Sinai Medical Center
Florida Cancer Center - Palatka
Piedmont Fayette Hospital
Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
Queen's Cancer Institute at Queen's Medical Center
Hawaii Medical Center - East
OSF St. Francis Medical Center
CCOP - Carle Cancer Center
Parkview Regional Cancer Center at Parkview Health
Cancer Center at Ball Memorial Hospital
Lucille P. Markey Cancer Center at University of Kentucky
Cape Cod Hospital
CentraCare Clinic - River Campus
Regional Cancer Center at Singing River Hospital
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
David C. Pratt Cancer Center at St. John's Mercy
Payson Center for Cancer Care at Concord Hospital
Seacoast Cancer Center at Wentworth - Douglass Hospital
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Elliot Regional Cancer Center at Elliot Hospital
Monmouth Medical Center
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
CCOP - Hematology-Oncology Associates of Central New York
Highland Hospital of Rochester
James P. Wilmot Cancer Center at University of Rochester Medical Center
Presbyterian Cancer Center at Presbyterian Hospital
Duke Cancer Institute
Pardee Memorial Hospital
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
Rex Cancer Center at Rex Hospital
Wake Forest University Comprehensive Cancer Center
Trinity CancerCare Center
Mercy Cancer Center at Mercy Medical Center
Case Comprehensive Cancer Center
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland Clinic Taussig Cancer Center
Cleveland Clinic Cancer Center
Hillcrest Cancer Center at Hillcrest Hospital
Parma Community General Hospital
Rosenfeld Cancer Center at Abington Memorial Hospital
Bryn Mawr Hospital
Geisinger Cancer Institute at Geisinger Health
Northeast Radiation Oncology Center
Adams Cancer Center
Cherry Tree Cancer Center
Cancer Center of Paoli Memorial Hospital
Lankenau Cancer Center at Lankenau Hospital
York Cancer Center at Apple Hill Medical Center
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
University of Texas Medical Branch
University of Texas Health Science Center at San Antonio
St. Joseph Cancer Center
St. Mary's Hospital Medical Center - Green Bay
St. Vincent Hospital Regional Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Arm Label

Supportive Care

Liquid Manuka Honey

Lozenge Manuka Honey

Arm Description

Standard supportive care

Manuka honey in liquid form

Manuka honey in lozenge form

Outcomes

Primary Outcome Measures

Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS)

Esophagitis-related pain was measured using patient-reported pain on swallowing as assessed by the Numerical Rating Pain Scale (NRPS), an 11-point scale (0-10) in which 0 indicates no pain and 10 indicates the worst pain imaginable. Generally, scores of 1-4 indicate mild pain, scores of 5-6 indicate moderate pain, and scores of 7-10 indicate severe pain. Change was calculated by subtracting the baseline value from the 4-week value. The experimental arms (honey) were compared to the standard arm (supportive care).

Secondary Outcome Measures

Radiation Esophagitis-related Pain During Treatment as Measured During Treatment and 12 Weeks by the Numerical Rating Pain Scale (NRPS)

Esophagitis-related pain was measured using patient-reported pain on swallowing as assessed by the Numerical Rating Pain Scale (NRPS), an 11-point scale (0-10) in which 0 indicates no pain and 10 indicates the worst pain imaginable. Generally, scores of 1-4 indicate mild pain, scores of 5-6 indicate moderate pain, and scores of 7-10 indicate severe pain. Change was calculated by subtracting the baseline value from values at the later time points. The experimental arms (honey) were compared to the standard arm (supportive care).

Dysphagia Via Daily Patient Log

Dysphagia, as reported by the patient, was measured by the patient swallowing diary. Swallowing score has increasing severity 1-5, where 1 = "none" and 5 = "cannot swallow liquids".

Quality of Life and Pain, as Measured by the EORTC QLQ-30 Global QOL Score and Pain Symptom Subscale at 4 and 12 Weeks

The pain symptom subscale (2 items) evaluated pain and the global score (30 items) evaluated quality of life. Each ranges from 0-100 with lower scores indicating lesser burden and improved symptoms or quality of life.

Percentage of Participants With Radiation Esophagitis Grade 3-4 (CTCAE v. 4)

Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. For esophagitis specifically, Grade 3 criteria includes severely altered eating/swallowing, tube feeding, total parenteral nutrition (TPN) or hospitalization indicated. Grade 4 criteria include life-threatening consequences, urgent operative intervention indicated.

Percent Change in Weight From Baseline to 4 Weeks

Nutritional Status (Change in Serum Prealbumin Levels From Baseline to 4 Weeks)

Percentage of Patients Using Opioids

The percentage of patients using opioid analgesics is reported. Use of opioid analgesics was assessed for a 24-hour period before completing the assessment. Patients with at least one reported administration of opioid analgesic were considered to have received opioid analgesics.

Adverse Events Associated With Manuka Honey Using CTCAE v4.0

Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.

Patient Reported Difficulty in Swallowing Associated With Manuka Honey Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Change from baseline to four weeks in patient-reported difficulty in swallowing via the PRO-CTCAE. PRO-CTCAE is an item bank consisting of individual items to assess adverse symptom events from the patient perspective. There are 78 symptoms included in the survey but the primary item of interest assesses difficulty swallowing. For each AE in the PRO-CTCAE, between 1 and 3 items are included to assess the frequency, severity, and/or interference with activities related to that AE. Frequency questions have responses ranging from never, which is scored as a 0, to almost constantly, which is scored as a 4. Severity questions have responses ranging from none, which is scored as a 0, to very severe, which is scored as a 4. Interference questions have responses ranging from not at all, which is scored as a 0, to very much, which is scored as a 4. Difficulty in swallowing only has a severity question.

Full Information

NCT ID

NCT01262560

First Posted

December 16, 2010

Last Updated

August 29, 2017

Sponsor

Radiation Therapy Oncology Group

Collaborators

National Cancer Institute (NCI), NRG Oncology

1. Study Identification

Unique Protocol Identification Number

NCT01262560

Brief Title

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Official Title

Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer

Study Type

Interventional

2. Study Status

Record Verification Date

August 2017

Overall Recruitment Status

Completed

Study Start Date

February 2012 (undefined)

Primary Completion Date

February 2014 (Actual)

Study Completion Date

November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Radiation Therapy Oncology Group

Collaborators

National Cancer Institute (NCI), NRG Oncology

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.

Detailed Description

OBJECTIVES: Primary Evaluate the relative efficacy of 4 times a day consumption of liquid or lozenge Manuka honey to delay or prevent radiation esophagitis-related pain (during combined chemotherapy and radiation therapy for lung cancer) as compared to standard supportive treatment, as measured at week 4 by Numerical Rating Pain Scale (NRPS) for pain upon swallowing. Secondary Evaluate the trend of severity of radiation esophagitis-related pain during combined chemotherapy and radiation therapy for lung cancer using weekly measurements of the NRPS. Evaluate the adverse events associated with Manuka honey, as measured by CTCAE, v. 4. Evaluate the severity of radiation esophagitis (grade 3-4, CTCAE, v. 4). Assess weight loss (percent weight change from baseline to 4 weeks). Assess quality of life (QOL) and pain, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-30) global QOL score and pain symptom subscale. Assess patient-reported dysphagia via a daily patient log. Assess nutritional status, as measured by the mean change in serum prealbumin levels from baseline to 4 weeks. Assess opioid use by collecting the patient's narcotic use in the previous 24-hour period at each weekly evaluation. Evaluate patient-reported adverse events associated with Manuka honey using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). OUTLINE: This is a multicenter study. Patients are stratified according to the percentage of esophagus in the radiation field (V60 < 30% vs V60 ≥ 30%). Patients are randomized to 1 of 3 treatment arms. Arm I: Patients receive standard supportive care for esophagitis-related pain as needed during chemoradiotherapy. Arm II: Patients swallow liquid Manuka honey slowly over 3-5 minutes. Patients must refrain from eating and drinking for 1 hour after administration. Treatment continues 4 times per day during chemoradiotherapy. Arm III: Patients place Manuka honey lozenges in their mouth one at a time and swallow the honey as it dissolves (no chewing or swallowing it whole). Patients must refrain from eating and drinking for 1 hour after administration. Treatment continues 4 times per day during chemoradiotherapy. Patients complete quality of life, pain swallowing diary, and pain assessments (Numerical Rating Pain Scale, EORTC QLQ-30 and Pain Subscale, and PRO-CTCAE) periodically during study treatment. Patients are followed up at 12 weeks from the start of study treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Dysphagia, Lung Cancer, Pain, Esophagitis

Keywords

pain, dysphagia, recurrent non-small cell lung cancer, stage IA non-small cell lung cancer, stage IB non-small cell lung cancer, stage IIA non-small cell lung cancer, stage IIB non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, extensive stage small cell lung cancer, limited stage small cell lung cancer, recurrent small cell lung cancer, esophagitis

7. Study Design

Primary Purpose

Supportive Care

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

163 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Supportive Care

Arm Type

Active Comparator

Arm Description

Standard supportive care

Arm Title

Liquid Manuka Honey

Arm Type

Experimental

Arm Description

Manuka honey in liquid form

Arm Title

Lozenge Manuka Honey

Arm Type

Experimental

Arm Description

Manuka honey in lozenge form

Intervention Type

Drug

Intervention Name(s)

Manuka honey in liquid form

Intervention Description

Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.

Intervention Type

Drug

Intervention Name(s)

Manuka honey in lozenge form

Intervention Description

Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.

Intervention Type

Drug

Intervention Name(s)

Standard supportive care

Intervention Description

Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®); Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed.

Primary Outcome Measure Information:

Title

Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS)

Description

Time Frame

Baseline and 4 weeks from the start of treatment

Secondary Outcome Measure Information:

Title

Radiation Esophagitis-related Pain During Treatment as Measured During Treatment and 12 Weeks by the Numerical Rating Pain Scale (NRPS)

Description

Esophagitis-related pain was measured using patient-reported pain on swallowing as assessed by the Numerical Rating Pain Scale (NRPS), an 11-point scale (0-10) in which 0 indicates no pain and 10 indicates the worst pain imaginable. Generally, scores of 1-4 indicate mild pain, scores of 5-6 indicate moderate pain, and scores of 7-10 indicate severe pain. Change was calculated by subtracting the baseline value from values at the later time points. The experimental arms (honey) were compared to the standard arm (supportive care).

Time Frame

Baseline, weekly during treatment, and 12 weeks from the start of treatment

Title

Dysphagia Via Daily Patient Log

Description

Dysphagia, as reported by the patient, was measured by the patient swallowing diary. Swallowing score has increasing severity 1-5, where 1 = "none" and 5 = "cannot swallow liquids".

Time Frame

Weekly during treatment and 12 weeks from the start of treatment

Title

Quality of Life and Pain, as Measured by the EORTC QLQ-30 Global QOL Score and Pain Symptom Subscale at 4 and 12 Weeks

Description

Time Frame

Baseline, 4 and 12 weeks from the start of treatment

Title

Percentage of Participants With Radiation Esophagitis Grade 3-4 (CTCAE v. 4)

Description

Time Frame

Up to 12 weeks from the start of treatment

Title

Percent Change in Weight From Baseline to 4 Weeks

Time Frame

Baseline and 4 weeks from the start of treatment

Title

Nutritional Status (Change in Serum Prealbumin Levels From Baseline to 4 Weeks)

Time Frame

Baseline and 4 weeks from the start of treatment

Title

Percentage of Patients Using Opioids

Description

Time Frame

Baseline, 4 weeks, end of radiation treatment, and 12 weeks from the start of treatment

Title

Adverse Events Associated With Manuka Honey Using CTCAE v4.0

Description

Time Frame

Until 12 weeks from the start of treatment

Title

Patient Reported Difficulty in Swallowing Associated With Manuka Honey Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Description

Time Frame

Baseline and 4 weeks from the start of treatment

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

DISEASE CHARACTERISTICS: Patients being treated with combination chemotherapy (definitive or adjuvant) and radiation therapy once daily for small cell or non-small cell lung cancer (primary population for the trial) Patients can receive chemoradiotherapy while on a Radiation Therapy Oncology Group (RTOG) lung trial or while not being on a clinical trial No patients receiving chemoradiotherapy while enrolled on a single institution trial or trials coordinated by other cooperative groups No patients with metastatic disease At least 5 cm of the esophagus must be in the 60 Gy isodose volume in 1.6 to 2.0 Gy fractions PATIENT CHARACTERISTICS: Age 18 and up Able to swallow thick liquids prior to treatment Able to speak English or Spanish in order to complete required forms (verbal completion is adequate) No patients with poorly controlled diabetes No known hypersensitivity to honey PRIOR CONCURRENT THERAPY: See Disease Characteristics No patients who have received prior chemotherapy or radiation therapy No patients receiving more than once daily treatments Therapeutic use of honey other than the Manuka honey provided for this trial is not allowed while patients are on study Patients must also avoid honey-flavored medical products and/or sugary, viscous substances Amifostine is not permitted

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Lawrence B. Berk, MD, PhD

Organizational Affiliation

Tampa General Hospital, University of South Florida

Official's Role

Principal Investigator

Facility Information:

Facility Name

Providence Cancer Center at Providence Hospital

City

Mobile

State/Province

Alabama

ZIP/Postal Code

36608

Country

United States

Facility Name

UCSF Helen Diller Family Comprehensive Cancer Center

City

San Francisco

State/Province

California

ZIP/Postal Code

94115

Country

United States

Facility Name

Stanford Cancer Center

City

Stanford

State/Province

California

ZIP/Postal Code

94305-5824

Country

United States

Facility Name

CCOP - Christiana Care Health Services

City

Newark

State/Province

Delaware

ZIP/Postal Code

19713

Country

United States

Facility Name

Baptist Cancer Institute - Jacksonville

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32207

Country

United States

Facility Name

CCOP - Mount Sinai Medical Center

City

Miami Beach

State/Province

Florida

ZIP/Postal Code

33140

Country

United States

Facility Name

Florida Cancer Center - Palatka

City

Palatka

State/Province

Florida

ZIP/Postal Code

32177

Country

United States

Facility Name

Piedmont Fayette Hospital

City

Fayetteville

State/Province

Georgia

ZIP/Postal Code

30214

Country

United States

Facility Name

Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler

City

Savannah

State/Province

Georgia

ZIP/Postal Code

31405

Country

United States

Facility Name

Queen's Cancer Institute at Queen's Medical Center

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96813

Country

United States

Facility Name

Hawaii Medical Center - East

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96817

Country

United States

Facility Name

OSF St. Francis Medical Center

City

Peoria

State/Province

Illinois

ZIP/Postal Code

61615-7827

Country

United States

Facility Name

CCOP - Carle Cancer Center

City

Urbana

State/Province

Illinois

ZIP/Postal Code

61801

Country

United States

Facility Name

Parkview Regional Cancer Center at Parkview Health

City

Fort Wayne

State/Province

Indiana

ZIP/Postal Code

46805

Country

United States

Facility Name

Cancer Center at Ball Memorial Hospital

City

Muncie

State/Province

Indiana

ZIP/Postal Code

47303-3499

Country

United States

Facility Name

Lucille P. Markey Cancer Center at University of Kentucky

City

Lexington

State/Province

Kentucky

ZIP/Postal Code

40536-0093

Country

United States

Facility Name

Cape Cod Hospital

City

Hyannis

State/Province

Massachusetts

ZIP/Postal Code

02601

Country

United States

Facility Name

CentraCare Clinic - River Campus

City

Saint Cloud

State/Province

Minnesota

ZIP/Postal Code

56303

Country

United States

Facility Name

Regional Cancer Center at Singing River Hospital

City

Pascagoula

State/Province

Mississippi

ZIP/Postal Code

39581

Country

United States

Facility Name

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63110

Country

United States

Facility Name

David C. Pratt Cancer Center at St. John's Mercy

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63141

Country

United States

Facility Name

Payson Center for Cancer Care at Concord Hospital

City

Concord

State/Province

New Hampshire

ZIP/Postal Code

03301

Country

United States

Facility Name

Seacoast Cancer Center at Wentworth - Douglass Hospital

City

Dover

State/Province

New Hampshire

ZIP/Postal Code

03820

Country

United States

Facility Name

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center

City

Lebanon

State/Province

New Hampshire

ZIP/Postal Code

03756-0002

Country

United States

Facility Name

Elliot Regional Cancer Center at Elliot Hospital

City

Manchester

State/Province

New Hampshire

ZIP/Postal Code

03103

Country

United States

Facility Name

Monmouth Medical Center

City

Long Branch

State/Province

New Jersey

ZIP/Postal Code

07740-6395

Country

United States

Facility Name

Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton

City

Marlton

State/Province

New Jersey

ZIP/Postal Code

08053

Country

United States

Facility Name

CCOP - Hematology-Oncology Associates of Central New York

City

East Syracuse

State/Province

New York

ZIP/Postal Code

13057

Country

United States

Facility Name

Highland Hospital of Rochester

City

Rochester

State/Province

New York

ZIP/Postal Code

14620

Country

United States

Facility Name

James P. Wilmot Cancer Center at University of Rochester Medical Center

City

Rochester

State/Province

New York

ZIP/Postal Code

14642

Country

United States

Facility Name

Presbyterian Cancer Center at Presbyterian Hospital

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28233-3549

Country

United States

Facility Name

Duke Cancer Institute

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27710

Country

United States

Facility Name

Pardee Memorial Hospital

City

Hendersonville

State/Province

North Carolina

ZIP/Postal Code

28791

Country

United States

Facility Name

FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center

City

Pinehurst

State/Province

North Carolina

ZIP/Postal Code

28374

Country

United States

Facility Name

Rex Cancer Center at Rex Hospital

City

Raleigh

State/Province

North Carolina

ZIP/Postal Code

27607

Country

United States

Facility Name

Wake Forest University Comprehensive Cancer Center

City

Winston-Salem

State/Province

North Carolina

ZIP/Postal Code

27157-1096

Country

United States

Facility Name

Trinity CancerCare Center

City

Minot

State/Province

North Dakota

ZIP/Postal Code

58701

Country

United States

Facility Name

Mercy Cancer Center at Mercy Medical Center

City

Canton

State/Province

Ohio

ZIP/Postal Code

44708

Country

United States

Facility Name

Case Comprehensive Cancer Center

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44106-5065

Country

United States

Facility Name

Cleveland Clinic Cancer Center at Fairview Hospital

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44111

Country

United States

Facility Name

Cleveland Clinic Taussig Cancer Center

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44195

Country

United States

Facility Name

Cleveland Clinic Cancer Center

City

Independence

State/Province

Ohio

ZIP/Postal Code

44131

Country

United States

Facility Name

Hillcrest Cancer Center at Hillcrest Hospital

City

Mayfield Heights

State/Province

Ohio

ZIP/Postal Code

44124

Country

United States

Facility Name

Parma Community General Hospital

City

Parma

State/Province

Ohio

ZIP/Postal Code

44129

Country

United States

Facility Name

Rosenfeld Cancer Center at Abington Memorial Hospital

City

Abington

State/Province

Pennsylvania

ZIP/Postal Code

19001

Country

United States

Facility Name

Bryn Mawr Hospital

City

Bryn Mawr

State/Province

Pennsylvania

ZIP/Postal Code

19010

Country

United States

Facility Name

Geisinger Cancer Institute at Geisinger Health

City

Danville

State/Province

Pennsylvania

ZIP/Postal Code

17822-0001

Country

United States

Facility Name

Northeast Radiation Oncology Center

City

Dunmore

State/Province

Pennsylvania

ZIP/Postal Code

18512

Country

United States

Facility Name

Adams Cancer Center

City

Gettysburg

State/Province

Pennsylvania

ZIP/Postal Code

17325

Country

United States

Facility Name

Cherry Tree Cancer Center

City

Hanover

State/Province

Pennsylvania

ZIP/Postal Code

17331

Country

United States

Facility Name

Cancer Center of Paoli Memorial Hospital

City

Paoli

State/Province

Pennsylvania

ZIP/Postal Code

19301-1792

Country

United States

Facility Name

Lankenau Cancer Center at Lankenau Hospital

City

Wynnewood

State/Province

Pennsylvania

ZIP/Postal Code

19096

Country

United States

Facility Name

York Cancer Center at Apple Hill Medical Center

City

York

State/Province

Pennsylvania

ZIP/Postal Code

17405

Country

United States

Facility Name

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

City

Spartanburg

State/Province

South Carolina

ZIP/Postal Code

29303

Country

United States

Facility Name

University of Texas Medical Branch

City

Galveston

State/Province

Texas

ZIP/Postal Code

77555-0361

Country

United States

Facility Name

University of Texas Health Science Center at San Antonio

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78229-3900

Country

United States

Facility Name

St. Joseph Cancer Center

City

Bellingham

State/Province

Washington

ZIP/Postal Code

98225

Country

United States

Facility Name

St. Mary's Hospital Medical Center - Green Bay

City

Green Bay

State/Province

Wisconsin

ZIP/Postal Code

54303

Country

United States

Facility Name

St. Vincent Hospital Regional Cancer Center

City

Green Bay

State/Province

Wisconsin

ZIP/Postal Code

54307-3508

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

We'll reach out to this number within 24 hrs